Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Low-Dose Aspirin Label Could Pose High Commercial Hurdle For Brilinta

Executive Summary

AstraZeneca could face a significant commercial challenge for its antiplatelet agent Brilinta (ticagrelor) if, as expected, FDA approves the drug with a recommendation for concomitant use of low-dose aspirin in acute coronary syndrome patients

You may also be interested in...



Brilinta Approval Shows AstraZeneca's Success With Aspirin Theory, But Can It Change The Market?

FDA appears to have come around to the "aspirin hypothesis" offered by AstraZeneca PLC to explain poor results for North American patients who took the blood-thinner Brilinta, though labeling takes a somewhat cautious approach that reflects initial concerns about that explanation.

Brilinta Approval Shows AstraZeneca's Success With Aspirin Theory, But Can It Change The Market?

FDA appears to have come around to the "aspirin hypothesis" offered by AstraZeneca PLC to explain poor results for North American patients who took the blood-thinner Brilinta, though labeling takes a somewhat cautious approach that reflects initial concerns about that explanation.

Brilinta "Complete Response" Letter Suggests FDA Unswayed On U.S. Efficacy

Agency asks AstraZeneca for additional analyses of data from the 18,000-patient PLATO study, in which no benefit of ticagrelor over clopidogrel was seen in U.S. acute coronary syndrome patients.

Related Content

Topics

UsernamePublicRestriction

Register

SC143162

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel